BPC-157

BPC-157, short for Body Protection Compound 157 and also called PL 14736 in older papers, is a synthetic peptide of 15 amino acids modelled on a fragment of a protein found in human gastric juice. It was developed by a research group in Zagreb, which has published the large majority of the literature on it over three decades. It is discussed on fitness and biohacking forums for gut healing, tendon injury, and “leaky gut”, and it is sold online by vendors who label it a research chemical not for human use.

What the science actually consists of is animal experiments. A 2020 review by the Zagreb group summarises work in rats showing that BPC-157 protects stomach lining cells from alcohol and non-steroidal anti-inflammatory drugs, counteracts injury to the gastric endothelium, promotes new blood-vessel routes around blocked vessels, and affects wound healing in skin, tendon, muscle, and other tissues PMID 31158953. A companion review proposes that it may stabilise intestinal permeability after NSAID exposure, again on the basis of rodent models PMID 32445447. These are mechanistic studies with specific injury models, mostly from a single laboratory, and the reviews are written by the compound’s developers. There are no randomised trials in people with IBS, and no human trials of any size that would allow a statement about efficacy or safety in a gut disorder.

The regulatory status is clear even if the marketing is not. BPC-157 is not approved as a medicine by the FDA or any other major regulator. In the United States, the FDA has placed it on its list of bulk drug substances nominated for compounding that may present significant safety risks, noting possible immunogenicity depending on route of administration, complexities in characterising peptide impurities, and no or only limited safety information, so that the agency “lacks sufficient information to know whether the drug would cause harm when administered to humans” (see the guideline link above). The FDA’s Pharmacy Compounding Advisory Committee scheduled BPC-157 for discussion at its July 2026 meeting, with a briefing document laying out the agency’s assessment. Products sold as research chemicals are not manufactured to pharmaceutical standards and are not tested for identity, purity, or dose, and they are typically injected or taken by mouth without any clinical oversight.

Points clinicians commonly raise: a rat ulcer model is not a person with IBS, and most compounds that look promising in animals do not translate; the word “peptide” does not make something gentle, since peptides can provoke immune responses; buying an unregulated injectable from a website carries risks that have nothing to do with the molecule; and the honest summary is that nobody knows whether BPC-157 does anything for IBS, because the question has never been studied in humans.

Talk to a clinician before starting or stopping anything.